Blog

Home  /  EUnetHTA Joint Action 3 (2016-2021)   /  PTJA09 – Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)

PTJA09 – Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)

This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for Beovu® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and safety of brolucizumab in the target patient population with relevant comparators according to the national requirements of EUnetHTA partners.

Below is the documentation provided by the Joint Assessment authoring team (project plan, assessment report and responses to the factual accuracy check) and by Novartis, the Marketing Authorisation Holder of brolucizumab (PTJA09 submission dossier).

For any questions regarding the assessment, please contact WP4_Pharmaceuticals@zinl.nl

PTJA09 –  Final Project Plan

PTJA09 – Final Assessment report

PTJA09 – MAH Core Submission Dossier

PTJA09 – External Comments – Factual Accuracy Check MAH